Advertisement
open access
Medical Conferences
Conference Reports
Conference Proceedings
Other Medical News
Multimedia
Podcast Channel
Videos
Webinar
About
2024 Medicom Conference Planning
Conference Proceedings-3
Home
>
Oncology
>
ESMO 2023
ESMO 2023
European Society for Medical Oncology
20
–
24 October 2023 Madrid, Spain
Table of Contents
Colophon
Table of Contents
Featured articles
Letter from the Editor
Editor
Dr Stefan Rauh, Centre Hospitalier Emile Mayrisch, Luxembourg
The importance of detecting early NSCLC
Expert
Prof. Witold Rzyman, Medical University of Gdańsk, Poland
ESMO 2023 Highlights Podcast
Presented By
Dr Rachel Giles, Medicom
Breast Cancer
Benefit of pembrolizumab in TNBC remains after 5 years of follow-up
Presented By
Prof. Peter Schmid, Barts Cancer Institute, UK
Addition of pembrolizumab promising in early-stage high-risk ER+/HER2- breast cancer
Presented By
Dr Fatima Cardoso, Champalimaud Clinical Centre, Portugal
Long-term air pollution exposure at both residential and workplace locations increases breast cancer risk
Presented By
Prof. Béatrice Fervers, Centre Léon Bérard, France
Third-line datopotamab deruxtecan improves progression-free survival in previously treated metastatic HR+/HER2- breast cancer compared with chemotherapy
Presented By
Dr Aditya Bardia, Massachusetts General Hospital, USA
Colorectal Cancer
Neoadjuvant nivolumab/relatlimab demonstrates 100% pathological response in MMRd colon cancer
Presented By
Dr Yara Verschoor, Netherlands Cancer Institute, the Netherlands
Selective KRASG12C inhibitor sotorasib leads to superior PFS in colorectal cancer
Presented By
Dr Filippo Pietrantonio, Istituto Nazionale dei Tumori, Italy
Postoperative ctDNA predicts survival in colorectal cancer
Presented By
Dr Yoshiaki Nakamura, National Cancer Centre Hospital East, Japan
Overall survival in patients with initially unresectable colorectal liver metastases does not depend on choice of induction regimen
Presented By
Prof. Cornelis J. Punt, University Medical Center Utrecht, the Netherlands
Lung Cancer
Perioperative nivolumab boosts event-free survival in NSCLC
Presented By
Dr Tina Cascone, MD Anderson Cancer Center, USA
Selective RET inhibitor selpercatinib doubles progression-free survival in RET-mutated NSCLC
Presented By
Prof. Herbert Ho Fung Loong, Chinese University of Hong Kong, China
Dato-DXd outperforms docetaxel in previously treated patients with metastatic NSCLC
Presented By
Dr Aaron Lisberg, University of California Los Angeles, USA
First-line and second-line benefit of amivantamab in advanced, EGFR-mutated NSCLC
Presented By
Prof. Nicolas Girard, Institut du Thorax Curie-Montsouris, France
Upper Gastro-Intestinal Cancer
Perioperative durvalumab/FLOT improves pCR in gastric cancer
Presented By
Prof. Salah-Eddin Al-Batran, Northwest Hospital Frankfurt, Germany
Active surveillance after neoadjuvant chemoradiotherapy in oesophageal cancer
Presented By
Dr Berend van der Wilk, Erasmus Medical Centre, the Netherlands
FOLFIRINOX equals gemcitabine-based chemoradiotherapy in neoadjuvant setting for pancreatic cancer
Presented By
Prof. Bas Groot Koerkamp, Erasmus Medical Centre, the Netherlands
Modified FLOT regime outperforms FOLFOX in advanced/metastatic gastric/gastroesophageal junction adenocarcinoma
Presented By
Prof. Aziz Zaanan, Université Paris Cité, France
Melanoma
Lifileucel induces a durable response in heavily pretreated mucosal melanoma
Presented By
Dr Evidio Domingo-Musibay, Masonic Cancer Center, USA
Darovasertib/crizotinib combination: a potential first-line therapy in metastatic uveal melanoma
Presented By
Dr Meridith McKean, Tennessee Oncology, USA
Genito-Urinary Cancers
Two potential new first-line standards of care in metastatic urothelial cancer
Presented By
Prof. Thomas Powles, Queen Mary University of London, UK
LuPSMA and enzalutamide: a promising combination
Presented By
Prof. Louise Emmet, St Vincent’s Hospital Sydney, Australia
No benefit of erdafitinib over pembrolizumab in urothelial cancer second-line therapy
Presented By
Prof. Arlene Siefker-Radtke, MD Anderson Cancer Centre, USA
Gynaecological Cancers
Addition of atezolizumab to chemotherapy and maintenance PARP inhibitor has no benefit in ovarian cancer
Presented By
Prof. Antonio Gonzalez Martin, Cancer Centre Clinica Universidad de Navarre, Spain
Short-induction chemotherapy improves survival in advanced cervical cancer
Presented By
Dr Mary McCormack, University College London, UK
Neoadjuvant immune checkpoint blockade safe and effective in MMRd endometrial cancer
Presented By
Dr Marco de Bruyn , University Medical Center Groningen, the Netherlands
Featured Interviews
Can radiotracers predict response to PD-L1 inhibitors in early NSCLC?
Expert
Prof. Gary Cook, King's College London and Guy's and St Thomas Hospitals, UK
The importance of detecting early NSCLC
Expert
Prof. Witold Rzyman, Medical University of Gdańsk, Poland